The European Alliance of Associations for Rheumatology (EULAR) 2026 European Congress of Rheumatology
London, UK 03 June 2026 - 06 June 2026
Izokibep maintains PsA efficacy at 52 weeks
The novel small-protein IL-17 inhibitor izokibep demonstrates durable efficacy and a favourable safety profile over 52 weeks in patients with active psoriatic arthritis (PsA), with sustained improvements in joint, skin, and quality-of-life outcomes in a phase IIB/III study.
Bimekizumab tops risankizumab on ACR50 in psoriatic arthritis
Bimekizumab outperformed risankizumab in the American College of Rheumatology ≥50 percent response criteria (ACR50) among patients with active psoriatic arthritis (PsA) in the phase IIIb BE BOLD trial – the first head-to-head PsA study to demonstrate superiority for a joint-focused primary endpoint.
How does baricitinib compare in RA patients at risk of VTE?
Treatment with baricitinib misses the noninferiority mark against tumour necrosis factor inhibitors (TNFi) in active rheumatoid arthritis (RA) patients at risk for venous thromboembolism (VTE) with high baseline disease activity, reports a study.
Novel extended-release tablet superior to febuxostat at reducing SUA levels
An extended-release formulation, HR091506, performs better than febuxostat immediate release in lowering urate levels in patients with gout and hyperuricaemia, as shown in a phase III trial.
